1. Table 11.1 Some of the more frequent genetic abnormalities within haematological tumours
affecting the function of oncogenes.
Disease Genetic abnormality Oncogenes involved
AML t(8; 21) ETO/AML1 (CBFα)
t(15; 17) PML, RARA
Nucleotide insertion NPM
Mutation, ITD FLT3
Mutation TET-2
Secondary AML 11q 23 translocations MLL
Myelodysplasia – 5, del (5q)
– 7, del (7q)
RPS 14
N RAS
CML t(9; 22) BCR-ABL1
Myeloproliferative Point mutation JAK-2
Point mutation TET-2
B-ALL t(12; 21) TEL/AML1
t(9; 22) BCR-ABL1
t(4; 11) AF4/MLL
Follicular lymphoma t(14; 18) BCL2
Mantle cell lymphoma t(11; 14) Cyclin D1
Burkitt lymphoma t(8; 14) MYC
CLL 17p deletion P53
11q 22-23 deletion ATM
AML, acute myeloid leukaemia; B-ALL, B-acute lymphoblastic leukaemia; CLL, chronic lymphocytic leukaemia; CML, chronic
myeloid leukaemia; ITD, internal tandem duplication.